Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Schizophrenia is still remained one of the disabling disorders despite progress in treatment
of mental disturbances. Ten to thirty percents of patients have a little or no benefit from
treatment with all kinds of antipsychotics using adequate dosages and duration. Treatment of
these patients has remained a persistent public health problem since medication-resistant
patients are often highly symptomatic. Curcumin is one of the main curcuminoids isolated from
this perennial herb. It possesses a variety of pharmacological activities, including
anti-inflammatory, antiproliferative, antioxidant, and neuroprotective effects and crosses
the blood-brain barrier. The purpose of our suggested study is to examine the efficacy of
curcumin as add-on the conventional antipsychotic psychopharmacotherapy in chronic
schizophrenia patients.